Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2T3
UPID:
GUAD_HUMAN
Alternative names:
Guanine aminohydrolase; p51-nedasin
Alternative UPACC:
Q9Y2T3; B4DTY5; Q5SZC7; Q9H335; Q9ULG2
Background:
Guanine deaminase, also known as guanine aminohydrolase or p51-nedasin, plays a crucial role in nucleotide metabolism by catalyzing the hydrolytic deamination of guanine to produce xanthine and ammonia. This enzymatic process is vital for the catabolism of guanine, an essential purine base in DNA and RNA, into xanthine, which is further processed in the purine degradation pathway.
Therapeutic significance:
Understanding the role of Guanine deaminase could open doors to potential therapeutic strategies. Its pivotal function in purine metabolism suggests that modulation of its activity could have implications for disorders related to nucleotide imbalance or purine metabolism dysregulation.